PubMed Health⌕ Search

Biomedical subjects

N Gingold

Publications and source records attributed to N Gingold.

5 recordsLinked to original sources
PubMed1979

[Blood histamine level in chronic myeloproliferative diseases; a review].

Since the discovery of a very high blood histamine level in chronic myelocytic leukemia (CML) 1936, the author could ascertain that this parameter is very useful in the differential diagnosis between CML and various "leukemoid" reactions; in the early diagnosis of CML and in the differential diagnosis between CML and other myeloproliferative disorders. Recent researches proved that no correlation exists between blood histamine level and basophil count in the peripheral blood. Further investigations in this field have to clear up the questions whether it is possible by means of repeated controls of the blood histamine level to predict the development of a polycythemia vera into CML or to establish in a case of osteomyelosclerosis that this disease has been Preceeded by A CML.

Animals↗
PubMedDate not supplied

Ph1-positive polycythemia vera.

The rare presence of the ph1 chromosome in chronic myeloproliferative disorders other than chronic granulocytic leukemia (CGL), i.e. polycythemia vera (PV), myeloid metaplasia with myelofibrosis (MMM) and hemorrhagic thrombocytopenia (HT) raised the question whether or not the Ph1 chromosome is peculiar to CGL. In an attempt to answer this question, the authors reports six cases of positive-Ph1 of which two are from their personal experience and four from the literature. Three of these six cases converted to CGL. The authors conclude that the cases of Ph1-positive PV and HT are transition forms to CGL, and the cases of Ph1-positive MMM are in fact secondary forms derived from CGL.

Adult↗
PubMedDate not supplied

A preventive therapy of the central nervous system complications in acute leukemias. Preliminary report.

A new therapeutic schedule for preventive therapy of the central nervous system (CNS) complications by intrathecal (i.t.) injections of methotrexate (MTX) was applied in two groups of 6 and respectively 13 adults with acute lymphoblastic or non-lymphoblastic leukemias. Instead of starting this treatment only in the remission stage, i.t. MTX was given from the very beginning of cytostatic therapy. In most of the patients this drug proved to be effective in preventing CNS involvement. In some cases, however, it was not well, tolerated owing probably to a neurotoxic effect. This suggested continuation of the study with Ara-C.

Adolescent↗